Laureen S. Ojalvo MD, PhD

Laureen Ojalvo is a Senior Director of Early Clinical Development and Oncology at the Bristol Myers Squibb. She is the medical lead for the phase 1 study of this molecule which included a dose-escalation part followed by a large expansion phase and a recently initiated randomized lung trial which was predicated on the phase 1 data. She received her MD and Ph.D. degrees from the Albert Einstein College of Medicine Medical Scientist Training Program and completed her doctoral research on tumor-associated macrophages in the laboratory of Dr. Jeffrey Pollard.